从3035例孕妇中筛查出HBV无症状携带者166例,其中HBsAg单阳性113例,HBsAg、HBeAg双阳性53例,共生婴儿166例。HBsAg单阳性孕妇临产前3个月每月注射乙肝免疫球蛋白(HBIG)200 IU,HBsAg、HBeAg双阳性孕妇临产前3个月每月注射HBIG 400 IU;新生儿出生时和出生2周时各注射HBIG 200 IU,接着在出生1、2、7个月时各接种HBIG 10 μg重组(酶母)乙肝疫苗;接着在婴儿出生后1、7、12、24个月定期抽血作二对半测定。结果:婴儿出生后1、7、12、24个月时HBsAg阳性率分别为4.22％、3.61％、3.66％、3.68％,抗-HBs阳性率(保护率)分别为74.10％、81.93％、95.12％、98.16％,母婴传播阻断率达95％以上。提示HBIG与重组(酵母)乙肝疫苗联合应用免疫效果好,安全可采用。 A total of 166 asymptomatic carriers of HBV were screened out from 3,035 pregnant women, of which 113 were single positive for HBsAg, 53 were positive for HBsAg and HBeAg, and 166 were symbiotic infants. HBsAg single-positive pregnant women were injected with 200 IU of hepatitis B immunoglobulin (HBIG) monthly for three months before giving birth, and 100 IU HBsAg and HBeAg positive pregnant women were injected with HBIG 400 IU three months before giving birth. Neonates were born at birth and two weeks HBIG 200 IU was injected followed by HBIG 10 μg recombinant (enzyme mother) hepatitis B vaccine at 1, 2, and 7 months of age; followed by regular blood draws at 2, 1, 2, and 4 months after birth Determination. Results: The positive rates of HBsAg in infants at 1, 7, 12 and 24 months after birth were 4.22%, 3.61%, 3.66% and 3.68%, respectively. The positive rates of anti-HBs were 74.10%, 81.93% and 95.12, respectively %, 98.16%, mother-to-child transmission blocking rate of 95% or more. Prompt HBIG and recombinant (yeast) hepatitis B vaccine combined with good immune effect, safety can be used.